Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Study to assess venetoclax followed by venetoclax + azacitidine and donor lymphocyte infusion
(DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with
blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).